1. Canada Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
Linike Medical Group Ltd

Linike Medical Group Ltd

LNMG
Linike Medical Group LtdUS flagOther OTC
0.01
USD
- -
- -
6.11MMarket Cap
2011 Y
2012 Y
2013 Y
TTM
Revenue per Share
0.08
- -
- -
- -
Basic EPS, GAAP
-0.21
-0.21
-0.25
-0.09
Free Cash Flow per Basic Share
-0.23
- -
-0.02
0.03
Dividend per Share
- -
- -
- -
- -
Book Value per Share
-0.09
-0.2
-0.28
-0.16
Tangible Book Value per Share
0.48
-0.2
-0.28
-0.15
Basic Weighted Avg Shares
- -
- -
2
3
Sales/Revenue/Turnover
- -
- -
- -
- -
Operating Margin (%)
-269.03
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
-268.82
- -
- -
- -
Working Capital
- -
- -
- -
-1
LT Debt
- -
- -
- -
- -
Total Equity
- -
- -
- -
-1
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jan'14
Apr'14
Jul'14
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
11
14
61

Working Capital

FRC

•

in mil. unless spec.
Jan'14
Apr'14
Jul'14
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
1
1
Payables & Accruals
- -
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
778.65%
Free Cash Flow
- -
- -
11,817.15%
Net Income, GAAP
- -
- -
651.28%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2012
-0.1
-0.14
-0.05
- -
-0.21
2013
-0.13
-0.05
-0.04
- -
-0.25
2014
-0.01
-0.01
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Eric David Lawson
Sector
Financial Services
Industry
Shell Companies
Address
833–1st Avenue NW Calgary AB Canada T2N 0A4
IPO Date
Jun 12, 2012
Website
dinoenergycorporation.com
Similar Companies
Cantor Equity Partners, Inc. Class A Ordinary Shares (CEP)
XCana Petroleum Corporation (XCPT)
Lionheart Holdings (CUB)
Levere Holdings Corp. (LVRAW)
Bilander Acquisition Corp. (TWCB)
IGS Capital Group Limited (IGSC)
Business
Linike Medical Group Ltd specializes in the research, development, production, and sale of large-scale external beam therapy equipment, specifically medical electron linear accelerators used for cancer treatment. The company operates primarily in the healthcare and medical devices sector with a focus on oncology treatment solutions. It has key subsidiaries including China Linike Medical Group Ltd, a British Virgin Islands corporation, and Sichuan Huarong Zhengtai Medical Technology Co., Ltd, which support its operations primarily in China. Founded on March 11, 2011, Linike Medical Group is headquartered in Chengdu, China. The company has recently undergone strategic organizational changes, including acquiring 100% ownership interest in its subsidiary China Linike Medical Group Ltd through a transaction completed in December 2022. This consolidation aims to streamline operations and enhance its R&D capabilities. Linike Medical Group has focused on expanding its product portfolio in advanced cancer treatment technology, maintaining its position in the external beam therapy market. It is currently exploring new business operations to further diversify its growth potential. Linike Medical Group is listed with the ticker LNMG and operates primarily in the Chinese and broader Asian markets. The company's product range centers on electron linear accelerators for cancer treatment, positioning it as a key player in medical radiation therapy equipment manufacturing. It leverages its technological expertise to develop cutting-edge treatment devices that serve hospitals and oncology centers. Its recent strategic acquisition and ongoing business development efforts highlight its commitment to growth in the medical devices industry.